WHAT IS CLAIMED IS:

1. A composition comprising a plurality of intact and bacterial derived minicells, wherein each minicell encloses at least about 500,000 molecules of PNU-159682, wherein the minicell further comprises a bispecific antibody comprising (i) a first arm with specificity for a minicell surface structure and (ii) a second arm with specificity for epidermal growth factor receptor (EGFR), and wherein the composition further comprises a minicell comprising a therapeutic nucleic acid molecule.

2. The composition of claim 1, wherein the epidermal growth factor receptor (EGFR) is in a brain tumor.

3. The composition of claim 1 or 2, wherein the minicell encloses at least about 200 ng of PNU-159682.

4. The composition of any one of claims 1-3, wherein the therapeutic nucleic acid molecule comprises an RNA sequence.

5. The composition of any one of claims 1-4, wherein the therapeutic nucleic acid molecule comprises or corresponds to a gene that is associated with tumor suppression selected from the p53 gene, the retinoblastoma gene, and the gene encoding tumor necrosis factor.

6. Use of an effective amount of a composition according to any one of claims 1-5, wherein the compound is cytotoxic, in the manufacture of a medicament for treating cancer in a patient in need thereof.